A

	Very unlikely		Somewhat unlikely		Somewhat likely		Very likely		Total	Weighted average (1 very unlikely; 4 very likely)
All patients	4.00%	1	8.00%	2	44.00%	11	44.00%	11	25	3.28
Ki-67 < 10%	3.85%	1	3.85%	1	19.23%	5	73.08%	19	26	3.62
Ki-67 10%-20%	3.85%	1	3.85%	1	50.00%	13	42.31%	11	26	3.31
If functioning tumour (carcinoid syndrome)	3.85%	1	3.85%	1	23.08%	6	69.23%	18	26	3.58
If non-functioning tumour (absence of carcinoid syndrome)	3.85%	1	3.85%	1	38.46%	10	53.85%	14	26	3.42
Somatostatin receptor imaging has shown positivity	3.85%	1	0.00%	0	7.69%	2	88.46%	23	26	3.81
Somatostatin receptor imaging has shown negativity	88.46%	23	11.54%	3	0.00%	0	0.00%	0	26	1.12
Somatostatin receptor imaging showed heterogeneous uptake	11.54%	3	61.54%	16	23.08%	6	3.85%	1	26	2.19
Age < 50 years old	3.85%	1	3.85%	1	15.38%	4	76.92%	20	26	3.65
Age > 50 years old	3.85%	1	3.85%	1	11.54%	3	80.77%	21	26	3.69
Age < 70 years old	3.85%	1	3.85%	1	11.54%	3	80.77%	21	26	3.69
Age > 70 years old	7.69%	2	3.85%	1	23.08%	6	65.38%	17	26	3.46
Low tumour burden	3.85%	1	19.23%	5	46.15%	12	30.77%	8	26	3.04
High tumour burden	3.85%	1	15.38%	4	15.38%	4	65.38%	17	26	3.42
Limited skeletal involvement	3.85%	1	7.69%	2	19.23%	5	69.23%	18	26	3.54
Extensive skeletal involvement	3.85%	1	7.69%	2	38.46%	10	50.00%	13	26	3.35
Rapid progression (< 6 mo)	11.54%	3	11.54%	3	42.31%	11	34.62%	9	26	3
Slow progression (> 1 yr)	3.85%	1	3.85%	1	19.23%	5	73.08%	19	26	3.62
Slow progression (> 2 yr)	3.85%	1	11.54%	3	30.77%	8	53.85%	14	26	3.35
TOTAL										**3.270526316**

B

	Very unlikely		Somewhat unlikely		Somewhat likely		Very likely		Total	Weighted average (1 very unlikely; 4 very likely)
As first-line treatment	65.38%	17	26.92%	7	7.69%	2	0.00%	0	26	1.42
As second-line treatment	19.23%	5	26.92%	7	46.15%	12	7.69%	2	26	2.42
As third-line treatment	3.85%	1	7.69%	2	50.00%	13	38.46%	10	26	3.23
After progression on all other available treatment options	3.85%	1	19.23%	5	34.62%	9	42.31%	11	26	3.15
Ki-67 < 10%	3.85%	1	3.85%	1	53.85%	14	38.46%	10	26	3.27
Ki-67 10%-20%	0.00%	0	15.38%	4	53.85%	14	30.77%	8	26	3.15
If functioning tumour (carcinoid syndrome)	11.54%	3	15.38%	4	53.85%	14	19.23%	5	26	2.81
If non-functioning tumour (absence of carcinoid syndrome)	0.00%	0	7.69%	2	65.38%	17	26.92%	7	26	3.19
Somatostatin receptor imaging has shown positivity	3.85%	1	7.69%	2	61.54%	16	26.92%	7	26	3.12
Somatostatin receptor imaging has shown negativity	0.00%	0	3.85%	1	69.23%	18	26.92%	7	26	3.23
Somatostatin receptor imaging showed heterogeneous uptake	0.00%	0	11.54%	3	65.38%	17	23.08%	6	26	3.12
Age < 50 years old	0.00%	0	3.85%	1	57.69%	15	38.46%	10	26	3.35
Age > 50 years old	0.00%	0	3.85%	1	61.54%	16	34.62%	9	26	3.31
Age < 70 years old	0.00%	0	7.69%	2	61.54%	16	30.77%	8	26	3.23
Age > 70 years old	0.00%	0	26.92%	7	65.38%	17	7.69%	2	26	2.81
Low tumour burden	3.85%	1	15.38%	4	61.54%	16	19.23%	5	26	2.96
High tumour burden	0.00%	0	19.23%	5	53.85%	14	26.92%	7	26	3.08
Limited skeletal involvement	3.85%	1	0.00%	0	65.38%	17	30.77%	8	26	3.23
Extensive skeletal involvement	0.00%	0	11.54%	3	61.54%	16	26.92%	7	26	3.15
Rapid progression (< 6 mo)	3.85%	1	26.92%	7	46.15%	12	23.08%	6	26	2.88
Slow progression (> 1 yr)	3.85%	1	11.54%	3	57.69%	15	26.92%	7	26	3.08
Slow progression (> 2 yr)	15.38%	4	11.54%	3	53.85%	14	19.23%	5	26	2.77
TOTAL										**2.998181818**

C

	Very unlikely		Somewhat unlikely		Somewhat likely		Very likely		Total	Weighted average (1 very unlikely; 4 very likely)
As first-line treatment	76.92%	20	19.23%	5	3.85%	1	0.00%	0	26	1.27
As second-line treatment	61.54%	16	34.62%	9	3.85%	1	0.00%	0	26	1.42
As third-line treatment	23.08%	6	34.62%	9	42.31%	11	0.00%	0	26	2.19
After progression on all other available treatment options	3.85%	1	3.85%	1	50.00%	13	42.31%	11	26	3.31
Ki-67 < 10%	61.54%	16	23.08%	6	15.38%	4	0.00%	0	26	1.54
Ki-67 10%-20%	3.85%	1	19.23%	5	73.08%	19	3.85%	1	26	2.77
If functioning tumour (carcinoid syndrome)	11.54%	3	42.31%	11	46.15%	12	0.00%	0	26	2.35
If non-functioning tumour (absence of carcinoid syndrome)	19.23%	5	34.62%	9	42.31%	11	3.85%	1	26	2.31
Somatostatin receptor imaging has shown positivity	23.08%	6	42.31%	11	34.62%	9	0.00%	0	26	2.12
Somatostatin receptor imaging has shown negativity	3.85%	1	30.77%	8	61.54%	16	3.85%	1	26	2.65
Somatostatin receptor imaging showed heterogeneous uptake	11.54%	3	26.92%	7	57.69%	15	3.85%	1	26	2.54
Age < 50 years old	15.38%	4	19.23%	5	53.85%	14	11.54%	3	26	2.62
Age > 50 years old	11.54%	3	30.77%	8	50.00%	13	7.69%	2	26	2.54
Age < 70 years old	11.54%	3	30.77%	8	46.15%	12	11.54%	3	26	2.58
Age > 70 years old	15.38%	4	42.31%	11	42.31%	11	0.00%	0	26	2.27
Low tumour burden	38.46%	10	38.46%	10	23.08%	6	0.00%	0	26	1.85
High tumour burden	3.85%	1	23.08%	6	65.38%	17	7.69%	2	26	2.77
Limited skeletal involvement	15.38%	4	46.15%	12	38.46%	10	0.00%	0	26	2.23
Extensive skeletal involvement	3.85%	1	34.62%	9	53.85%	14	7.69%	2	26	2.65
Rapid progression (< 6 mo)	0.00%	0	3.85%	1	57.69%	15	38.46%	10	26	3.35
Slow progression (> 1 yr)	34.62%	9	23.08%	6	38.46%	10	3.85%	1	26	2.12
Slow progression (> 2 yr)	53.85%	14	34.62%	9	11.54%	3	0.00%	0	26	1.58
TOTAL										**2.319545455**

D

	Very unlikely		Somewhat unlikely		Somewhat likely		Very likely		Total	Weighted average (1 very unlikely; 4 very likely)
As first-line treatment	64.00%	16	16.00%	4	20.00%	5	0.00%	0	25	1.56
As second-line treatment	28.00%	7	24.00%	6	48.00%	12	0.00%	0	25	2.2
As third-line treatment	16.00%	4	12.00%	3	68.00%	17	4.00%	1	25	2.6
After progression on all other available treatment options	12.00%	3	16.00%	4	52.00%	13	20.00%	5	25	2.8
Ki-67 < 10%	8.00%	2	12.00%	3	72.00%	18	8.00%	2	25	2.8
Ki-67 10%-20%	12.00%	3	20.00%	5	60.00%	15	8.00%	2	25	2.64
If functioning tumour (carcinoid syndrome)	4.00%	1	12.00%	3	40.00%	10	44.00%	11	25	3.24
If non-functioning tumour (absence of carcinoid syndrome)	8.00%	2	36.00%	9	48.00%	12	8.00%	2	25	2.56
Somatostatin receptor imaging has shown positivity	8.00%	2	28.00%	7	56.00%	14	8.00%	2	25	2.64
Somatostatin receptor imaging has shown negativity	8.00%	2	20.00%	5	64.00%	16	8.00%	2	25	2.72
Somatostatin receptor imaging showed heterogeneous uptake	8.00%	2	24.00%	6	60.00%	15	8.00%	2	25	2.68
Age < 50 years old	4.00%	1	16.00%	4	60.00%	15	20.00%	5	25	2.96
Age > 50 years old	8.00%	2	16.00%	4	60.00%	15	16.00%	4	25	2.84
Age < 70 years old	8.00%	2	20.00%	5	56.00%	14	16.00%	4	25	2.8
Age > 70 years old	12.00%	3	28.00%	7	56.00%	14	4.00%	1	25	2.52
Low tumour burden	16.00%	4	24.00%	6	52.00%	13	8.00%	2	25	2.52
High tumour burden	20.00%	5	32.00%	8	44.00%	11	4.00%	1	25	2.32
Limited skeletal involvement	24.00%	6	24.00%	6	48.00%	12	4.00%	1	25	2.32
Extensive skeletal involvement	56.00%	14	28.00%	7	12.00%	3	4.00%	1	25	1.64
Rapid progression (< 6 mon)	24.00%	6	32.00%	8	40.00%	10	4.00%	1	25	2.24
Slow progression (> 1 yr)	8.00%	2	28.00%	7	56.00%	14	8.00%	2	25	2.64
Slow progression (> 2 yr)	4.00%	1	44.00%	11	44.00%	11	8.00%	2	25	2.56
TOTAL										2.536363636

E

	Very unlikely		Somewhat unlikely		Somewhat likely		Very likely		Total	Weighted average (1 very unlikely; 4 very likely)
As first-line treatment	100.00%	25	0.00%	0	0.00%	0	0.00%	0	25	1
As second-line treatment	96.00%	24	4.00%	1	0.00%	0	0.00%	0	25	1.04
As third-line treatment	91.67%	22	4.17%	1	4.17%	1	0.00%	0	24	1.13
After progression on all other available treatment options	58.33%	14	29.17%	7	12.50%	3	0.00%	0	24	1.54
Ki-67 < 10%	75.00%	18	12.50%	3	12.50%	3	0.00%	0	24	1.38
Ki-67 10%-20%	91.67%	22	4.17%	1	4.17%	1	0.00%	0	24	1.13
If functioning tumour (carcinoid syndrome)	58.33%	14	25.00%	6	12.50%	3	4.17%	1	24	1.63
If non-functioning tumour (absence of carcinoid syndrome)	83.33%	20	12.50%	3	4.17%	1	0.00%	0	24	1.21
Somatostatin receptor imaging has shown positivity	80.00%	20	12.00%	3	8.00%	2	0.00%	0	25	1.28
Somatostatin receptor imaging has shown negativity	83.33%	20	12.50%	3	4.17%	1	0.00%	0	24	1.21
Somatostatin receptor imaging showed heterogeneous uptake	83.33%	20	12.50%	3	4.17%	1	0.00%	0	24	1.21
Age < 50 years old	75.00%	18	16.67%	4	8.33%	2	0.00%	0	24	1.33
Age > 50 years old	79.17%	19	12.50%	3	8.33%	2	0.00%	0	24	1.29
Age < 70 years old	75.00%	18	20.83%	5	4.17%	1	0.00%	0	24	1.29
Age > 70 years old	75.00%	18	20.83%	5	4.17%	1	0.00%	0	24	1.29
Low tumour burden	75.00%	18	8.33%	2	16.67%	4	0.00%	0	24	1.42
High tumour burden	87.50%	21	8.33%	2	4.17%	1	0.00%	0	24	1.17
Limited skeletal involvement	75.00%	18	16.67%	4	8.33%	2	0.00%	0	24	1.33
Extensive skeletal involvement	83.33%	20	12.50%	3	4.17%	1	0.00%	0	24	1.21
Rapid progression (< 6 mo)	91.67%	22	4.17%	1	4.17%	1	0.00%	0	24	1.13
Slow progression (> 1 yr)	75.00%	18	20.83%	5	4.17%	1	0.00%	0	24	1.29
Slow progression (> 2 yr)	66.67%	16	12.50%	3	20.83%	5	0.00%	0	24	1.54
TOTAL										1.275

Supplementary Figure 1 Factors associated with use of somatostatin analogues, peptide receptor radionuclide therapy, everolimus, chemotherapy and Interferon-alpha. A: Factors associated with use of somatostatin analogues in the first-line setting; B: Factors associated with use of peptide receptor radionuclide therapy in the first-line setting; C: Factors associated with use of everolimus; D: Factors associated with use of chemotherapy; E: Factors associated with use of liver embolization; F: Factors associated with use of Interferon-alpha.